Prime Medicine (NYSE:PRME – Get Free Report) and NKGen Biotech (NYSE:NKGN – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.
Profitability
This table compares Prime Medicine and NKGen Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prime Medicine | N/A | -107.87% | -74.97% |
| NKGen Biotech | N/A | N/A | -479.36% |
Valuation and Earnings
This table compares Prime Medicine and NKGen Biotech”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prime Medicine | N/A | N/A | -$198.13 million | ($2.05) | -1.23 |
| NKGen Biotech | $80,000.00 | 252.84 | -$82.94 million | ($5.08) | -0.09 |
Analyst Ratings
This is a summary of current ratings and recommmendations for Prime Medicine and NKGen Biotech, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prime Medicine | 0 | 0 | 9 | 1 | 3.10 |
| NKGen Biotech | 0 | 0 | 0 | 0 | 0.00 |
Prime Medicine currently has a consensus target price of $13.13, suggesting a potential upside of 420.83%. Given Prime Medicine’s stronger consensus rating and higher probable upside, equities analysts plainly believe Prime Medicine is more favorable than NKGen Biotech.
Insider & Institutional Ownership
70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 23.5% of Prime Medicine shares are owned by insiders. Comparatively, 74.7% of NKGen Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
Prime Medicine has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.
Summary
Prime Medicine beats NKGen Biotech on 7 of the 12 factors compared between the two stocks.
About Prime Medicine
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.
About NKGen Biotech
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
